Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study

This trial observes and collects samples from patients before and after stem cell transplantation to learn more about how and why a complication called chronic graft-versus-host disease (GVHD) develops after stem cell transplantation. Performing close observation and various types of testing may enable doctors to notice symptoms or problems sooner than they would normally have been noticed and predict which patients will develop chronic GVHD.
Not Available
Not Available
Kitko, Carrie
Vanderbilt University


18 Years
Inclusion Criteria:

Adults age 18 or older

Scheduled for allogeneic HCT from any donor for any indication, with a risk of cGVHD of > 25% (see below in exclusion criteria for treatment plans with a cGVHD risk
Ability and willingness to comply with the intensive assessment schedule including evaluation every other month at a participating site

Ability to communicate in English or Spanish, to allow completion of patient surveys and clear communication with the study team

Exclusion Criteria:

Receipt of umbilical cord blood, bone marrow with post-transplant cyclophosphamide (peripheral blood with post-transplant cyclophosphamide is allowed), anti-thymocyte globulin, alemtuzumab, or ex-vivo T-cell depletion. These patients are excluded because they have a cGVHD risk of
Hematologic malignancy with active disease at the time of transplant. Minimal residual disease is allowed

Hematopoietic cell transplant co-morbidity index > 4 based on parameters known at time of enrollment

Prior allogeneic transplant

Prior autoimmune disease with ongoing symptoms

History of noncompliance

Inability to comply with study requirements due to geographic, logistic, social or any other factors

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: